Teva Pharmaceuticals
Teva and Alvotech face FDA rejection for Stelara biosimilar after Humira setbacks
Ongoing issues at the Alvotech manufacturing facility in Reykjavik have led to yet another FDA rejection, this time affecting the ...
Lilly secures Emgality’s future after judge invalidates Teva’s patents
A federal judge in Massachusetts has ruled in favor of Eli Lilly, overturning a $176.5 million jury verdict issued in ...
Teva Wins License to Launch Generic Vivitrol in 2027 After Patent Settlement with Alkermes
Teva Pharmaceuticals has secured a pivotal victory in a patent dispute settlement with Alkermes, the manufacturer of Vivitrol. This settlement ...
Teva and Glenmark Agree to $255M Settlement with DOJ in Price-Fixing Case
Teva and Glenmark Pharmaceuticals, implicated in a price-fixing scheme, are facing substantial penalties and divestiture mandates after reaching a deferred ...
Teva Gains Trial Postponement for Unique Appeal Strategy in Copaxone Case Against US Government
After an enduring three-year legal battle against allegations by the US government, Teva Pharmaceuticals has managed to secure a delay ...
With Austedo running and the Uzedy launch underway, Teva is beginning to show indications of improvement
With a fresh growth strategy in place and two successful recent launches, Teva seems to be stepping into a new ...
Teva sets aside $200 million in ‘advanced’ settlement negotiations to end the US price-fixing investigation
Teva, a pharmaceutical company facing a price-fixing indictment by the U.S. Department of Justice (DOJ), is taking steps to resolve ...
Teva Aims for Growth by 2027 After $4.25B Opioid Settlement
Teva Pharmaceutical is shifting its focus back to its core businesses in generics and biosimilars, seeing promising opportunities in both ...
Teva Seeks Appeal in Kickbacks Case Amid $10 Billion Trial Risk
Teva has been grappling with opioid litigation for several years, culminating in a multibillion-dollar settlement last year. However, the company ...
Teva’s CEO Francis Recruits Angus Grant, Former BeiGene Business Development Head
Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic drugs, has announced the appointment of a new executive to ...
Cabometyx patent battle is resolved by Exelixis and Teva with a 2031 generic license
Source – Exelixis Exelixis, the company behind the successful cancer drug Cabometyx, has been actively defending its intellectual property. In ...
